Impact
A bigger and stronger platform
The ASCO GU Symposium is the premier global forum for genitourinary cancer research, consistently delivering practice-changing data. The 2026 edition featured landmark trials including KEYNOTE-B15 (EV-304) showing significant event-free survival benefit with neoadjuvant enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer, PEACE-3 demonstrating a clear overall survival benefit with radium-223 plus enzalutamide in mCRPC, and LITESPARK-022 showing improved disease-free survival with belzutifan plus pembrolizumab in resected clear cell RCC. These results are reshaping standards of care across GU malignancies




